Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

Purpose

This is a prospective, open label, multi-center, self-controlled clinical study to demonstrate the safety and efficacy of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow.

Conditions

  • Skin Laxity
  • Wrinkle
  • Brow Lifting

Eligibility

Eligible Ages
Between 35 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  1. Healthy female and male subjects between the ages 35-80. 2. Non-Smoker. 3. Fitzpatrick skin type I-VI. 4. Desire to lift lax skin in the neck and submental and/or to lift the brows. 5. Able and willing to comply with all visit, treatment and evaluation schedules and requirements. 6. Able to understand and provide written Informed Consent 7. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.

Exclusion Criteria

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding. 2. Presence of any active systemic or local infections. 3. Presence of active local skin disease that may alter wound healing. 4. Severe solar elastosis. 5. History of Epileptic seizures. 6. History of severe migraine tendency. 7. History of smoking in past 10 years. 8. History of chronic drug or alcohol abuse. 9. Excessive subcutaneous fat on the cheeks. 10. Significant scarring in the area to be treated. 11. Severe or cystic facial acne, acutance uses during past 6 months. 12. Presence of a metal stent or implant in the facial area. 13. Inability to understand the protocol or to give informed consent. 14. On-going use of psychiatric medication. 15. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the past year; injectable filler of any type within the past year; Botox or fillers in the lower face within the past 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift, blepharoplasty, or brow lift (including contour threads) within the past 12 months. 16. Taking Isotretinoin or other oral retinoid within the past 6 months; taking psychiatric drugs, anti-platelet or anti-coagulant within the past 2 weeks. 17. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study. -

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Sofwave Treatment
In this arm (single) patients would be treated twice with Sofwave on the face and/or submental and neck.
  • Device: Sofwave Treatments
    The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.

Recruiting Locations

More Details

NCT ID
NCT04146584
Status
Completed
Sponsor
Sofwave Medical LTD

Detailed Description

This is a prospective, open label, multi-center, self-controlled clinical study to demonstrate the safety and efficacy of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow. Up to 112 healthy candidates who are seeking treatment from participating investigators will be enrolled at up to 5 participating study sites. Patients will receive 2 treatments (4-6 weeks ± 2 weeks apart) with the SofWave system and will be followed up to 3 months post the last treatment (FU2).